ChromaDex director Tony Lau resigns; Champion River to nominate successor

Niagen Bioscience, Inc.

Tony Lau notified ChromaDex of his resignation from the Board and Compensation Committee on Oct 19, 2021; effective date not yet determined.
Resignation not due to any disagreement with the company; follows Lau's resignation from his position at Horizon Ventures.
Champion River Ventures, which nominated Lau, intends to nominate a replacement director under the 2017 Securities Purchase Agreement.
Lau's departure is unrelated to company operations, policies, or practices.

item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Tony Lau

director

NAGE · Niagen Bioscience, Inc.

Filed: October 29, 2021, 7:59 PM ET

On October 19, 2021, Tony Lau notified ChromaDex Corporation (the “Company”) of his intention to resign from the board of directors of the Company (the “Board”) and as a member of the Compensation Committee of the Board.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 1.0

Tony Lau resigned as director at Niagen Bioscience, Inc..

Action: resigned
Role: director

Exact text from the filing

On October 19, 2021, Tony Lau notified ChromaDex Corporation (the “Company”) of his intention to resign from the board of directors of the Company (the “Board”) and as a member of the Compensation Committee of the Board.

View on SEC.gov

Niagen Bioscience, Inc. filing history →

Source: SEC EDGAR

accession 0001628280-21-020884

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.